Overview

Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx

Status:
Completed

Trial end date:
2005-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the effectiveness and safety of benzydamine hydrochloride 0.15% oral rinse to a vehicle oral rinse in the treatment of radiation-induced oral mucositis, and to compare the care normally used for radiation-induced oral mucositis to vehicle oral rinse to ensure that the vehicle does not have detrimental effects on the oral mucosa

Phase:

Phase 3

Details

Lead Sponsor:

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Collaborator:

Angelini

Treatments:

Benzydamine